A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema
Status:
Active, not recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
Indicated for the Treatment of Secondary Lymphedema Associated with the Treatment of Breast
Cancer.
Primary objective is to evaluate the safety and tolerability of a single dose of Lymfactin®
in patients with secondary lymphedema associated with the treatment of breast cancer.